Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're looking into using anavar alongside semaglutide, the most useful thing to say upfront is this: there is no clinical evidence base for this combination, and one of these substances — anavar (oxandrolone) — is a controlled anabolic steroid, not a licensed weight-management medicine in the UK. Semaglutide, prescribed as Wegovy, is a licensed, GLP-1 receptor agonist indicated for weight management in adults with obesity or weight-related conditions. These two substances sit in entirely different regulatory and clinical worlds, and understanding why matters for anyone weighing up their options.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The search for anavar and semaglutide together typically comes from one of two places: someone in the gym or fitness community who has already been using anavar and wants to know whether adding semaglutide is safe, or someone who has lost muscle mass on a GLP-1 medicine and has been told, somewhere online, that anavar might protect against it. Both are understandable starting points. Neither has a clean clinical answer.
Anavar is oxandrolone, a synthetic anabolic steroid derived from testosterone. In the UK it sits under Schedule 4 Part II of the Misuse of Drugs Regulations 2001 and is a Class C controlled substance. Importing it for personal use, or supplying it, is a criminal offence. It is not licensed in the UK for weight management or body composition in healthy adults. Some readers will know it from its legitimate medical history: oxandrolone has been used in clinical settings to address muscle wasting in serious illness, severe burns and recovery contexts, but those uses are tightly controlled and managed by specialist teams, not gym culture.
Semaglutide, by contrast, is licensed by the MHRA under the brand name Wegovy for adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition such as high blood pressure or type 2 diabetes. The NHS medicines page for semaglutide covers its licensed indications and the clinical rationale clearly.
Semaglutide works by mimicking a gut hormone that signals fullness and slows the rate at which the stomach empties. The result, as seen in the STEP 1 trial published in the New England Journal of Medicine, is significant average weight loss, roughly 15% of body weight over 68 weeks at the 2.4mg maintenance dose. That weight loss is not purely fat. Like any calorie-deficit-driven intervention, some loss of lean mass can occur alongside fat mass, particularly if protein intake and resistance exercise are not maintained. This is not unique to semaglutide; it is a feature of meaningful weight loss by any route.
The anavar question often enters here: proponents in fitness communities argue that oxandrolone preserves or builds lean tissue during a caloric deficit. There is some evidence in clinical populations (people with serious illness, for example) that oxandrolone has anabolic effects. But extrapolating that to healthy adults combining it with a GLP-1 medicine is a large leap. There are no published studies examining this combination's safety, and cardiovascular side effects of anabolic steroids (including adverse lipid profiles, blood pressure changes and cardiac remodelling) are well documented. Adding semaglutide, which itself affects heart rate in some people, into that picture creates an interaction profile that no clinical authority has evaluated.
Keep in mind the practical side too. Semaglutide should be stored in the fridge (many people keep it on the fridge door at home) and injected once weekly at a consistent time. Responsible use of any prescription medicine is built around a stable routine, not stacked with unregulated substances. If you're thinking through how semaglutide affects other aspects of health, those are questions a prescriber can actually address with you.
The worry about muscle loss during GLP-1 treatment is real enough that clinical guidelines now address it directly. NHS England's guidance on weight-management injections emphasises that patients should be supported with adequate protein intake and physical activity, particularly resistance-based exercise, as part of their treatment. This is the evidence-based answer to lean mass preservation, not an unlicensed controlled substance.
A prescriber managing your weight-loss treatment can review your diet, flag if your protein targets seem low, and refer you to a dietitian or exercise professional where appropriate. That is the clinical route. There is no scenario in which a UK-registered prescriber would recommend combining a licensed semaglutide prescription with anavar for body composition reasons, doing so would be outside any licensed indication and contrary to good clinical practice.
If you've read that combining semaglutide and anavar is common in certain communities, that may be true as a sociological observation. It does not make it safe, assessed or clinically supported. The absence of published harm data is not evidence of safety, it is evidence that the combination has not been studied in a controlled way. Anyone who tells you otherwise is working from forum posts, not pharmacology.
Questions about what you can take alongside semaglutide are worth putting to a prescriber directly. If you are working through the dose escalation schedule and want to understand what changes at each stage, our pages covering semaglutide 1 and semaglutide 2 set out what to expect as your dose increases. You can also explore what licensed weight-loss treatment looks like at nume, from eligibility to the clinical process involved.
If you'd like to talk through whether semaglutide is clinically appropriate for you (including how to preserve lean mass during treatment) our prescribers are available to review your situation. Speak to our prescribers and they'll walk you through the options honestly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.